NLRP3 and atherosclerosis: Pharmacologic inhibition of NLRP3 in these mice reduced plaque size and endothelial adhesion molecule expression, supporting inflammasome-targeted therapies as potential protective strategies against CHIP-driven atherosclerosis [40].